• We detected 9 hepatocarcinogenesis-related genes in chronic HCV cases.

• SFRP1, APC, RASSF1A, O6MGMT & P16 genes can be used as predictors of antiviral response.

• RASSF1A & p16 methylated genes might be helpful in predicting fibrosis stage.

INTRODUCTION
============

Chronic liver disease may be defined as a disease of the liver that lasts over a period of 6 months. It comprises liver pathologies such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma \[[@b1-cmh-2019-0051]\]. Hepatitis C virus (HCV) infection is one of the causes that associated with chronic liver diseases. Infections with the HCV are pandemic, and the World Health Organization (WHO) estimates a world-wide prevalence of 3%. In Middle Europe, about 1% of the population is infected, mostly with genotype 1 (85% in Austria). In developing countries, chronic hepatitis C (CHC) is the most prominent cause for liver cirrhosis, hepatocellular carcinoma and liver transplantation \[[@b2-cmh-2019-0051]\].

Ribavirin/pegylated-interferon combination therapy is currently the most effective treatment for hepatitis C infection. Clearance of this HCV can be predicted by a sustained virological response (SVR) \[[@b3-cmh-2019-0051]\]. The main predictors of SVR are HCV genotype, stage of fibrosis, baseline HCV RNA levels, the dose and duration of therapy, IL28B polymorphism, body mass index (BMI), age, insulin resistance, gender, the levels of alanine aminotransferase (ALT), gamma glutamyl-transferase (GGT), and co-infection with human immunodeficiency virus (HIV) or other hepatotropic virus \[[@b4-cmh-2019-0051]\]. Many authors have found that different types of cancer, including hepatocellular carcinoma (HCC), show distinct DNA methylation profiles; suggesting the existence of cancer-type specific methylation signatures \[[@b5-cmh-2019-0051]\]. Others have shown that the presence of hepatitis viruses, especially HCV, could play a role in accelerating the methylation process which is involved in HCC development, potentiate the progression of HCV related liver disease and affect its response to treatment \[[@b6-cmh-2019-0051],[@b7-cmh-2019-0051]\].

Molecular pathogenesis of hepatocarcinogenesis still unclear. However, it has been revealed that epigenetic changes, especially global DNA hypomethylation concomitant with locus-specific DNA hypermethylation in gene promoters, plays vital roles in carcinoma progression \[[@b8-cmh-2019-0051],[@b9-cmh-2019-0051]\]. DNA methylation markers could be utilized to detect human cancers in blood, plasma, secretion, or exfoliated cytology specimens and predict the risk of cancer development \[[@b10-cmh-2019-0051],[@b11-cmh-2019-0051]\]. Thus, cell free DNA circulating in plasma of chronic liver disease patients may represent a promising non-invasive alternative for HCC screening and monitoring. Progression from chronic hepatic inflammation to the fibrotic/cirrhotic stage is supported by numerous core pathways, observed in other fibrotic diseases, as well as tissue- or injury-specific pathways that are only activated in particular conditions \[[@b12-cmh-2019-0051],[@b13-cmh-2019-0051]\].

Therefore, the present work was applied to verify the previous results \[[@b7-cmh-2019-0051],[@b14-cmh-2019-0051]\], and elucidate the role of promoter methylation (PM) in the response to antiviral therapy, and its contribution to the development of fibrosis using some hepatocarcinogenesis-related genes such as SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, O6MGMT, and p16.

MATERIALS AND METHODS
=====================

Patient specimens
-----------------

This study was done on 159 Egyptian patients with chronic genotype 4 hepatitis C in addition to 100 healthy control group. These patients were eligible for ribavirin/pegylated interferon combination therapy. Selection of patients was based on clinical and histological examinations. Inclusion criteria were morphologic evidence of chronic hepatitis, normal renal function (normal creatinine level), normal prothrombin time, elevated hepatic function (elevated bilirubin, aspartate aminotransferase and ALT levels), normal cardiac enzymes, HIV-antibody (Ab) negative by ELISA, hepatitis B surface antigen (HBsAg) negative by ELISA and hepatitis B virus (HBV) DNA negative by polymerase chain reaction (PCR), and anti-HCV positive by ELISA. Informed consents were obtained from all the participants enrolled in the study, which was performed in accordance with the declaration of Helsinki, local and national laws.

Laboratory investigations
-------------------------

They were done, and HCV RNA was quantified using quantitative real time PCR \[[@b15-cmh-2019-0051]\] at baseline, after 12, 24, 48, and 72 weeks of anti-viral therapy. Histological examination was done on core needle biopsies to determine the grade of necro-inflammation and the stage of fibrosis according to the Metavir scoring system prior to treatment. For the steatosis assessment tool, it was confirmed histologically, and expressed as % values of fatty changed. Also, it was checked by abdominal ultrasonography, each criterion of none, minimal, mild, and moderate steatosis was demonstrated in [Table 1](#t1-cmh-2019-0051){ref-type="table"}. Clinical and laboratory follow up were done for every patient to report any adverse side effects and treatment response according to interferon treatment guidelines.

DNA extraction
--------------

DNA was extracted from patient's plasma before receiving ribavirin/pegylated interferon combination therapy, according to the previously published protocol \[[@b16-cmh-2019-0051]\]. DNA was extracted through a phenol/chloroform treatment. Briefly, equal volume of buffer equilibrated phenol (pH 7.0--7.5) was added to samples and vortexed. The upper aqueous layer was removed with a "cut down" pipette tip, and an equal volume of phenol/chloroform (1:1) was then added to the aqueous supernatant and vortexed. The upper aqueous layer was removed again in a similar fashion, and an equal volume of chloroform/isoamyl (24:1) was then added and vortexed. Sodium acetate (3 M) (pH 4.7--5.2) was added to the aqueous supernatant, followed with ice-cold ethanol. Samples were then incubated overnight at -8°C. After decantation of the liquid, the DNA pellet was recovered and dissolved in sterile water. The purity and integrity of the DNA was confirmed by carrying out β-actin gene amplification.

Bisulphate conversion and methylation-specific polymerase chain reaction (MSP)
------------------------------------------------------------------------------

After DNA extraction, it was subjected to bisulfite treatment using EZ DNA methylation kit that uses 300 ng of the extracted nucleic acid. This was followed by MSP using the primer sequences and the methylation-specific PCR conditions illustrated in [Table 2](#t2-cmh-2019-0051){ref-type="table"}. DNA methylation of CpG islands for SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, O6MGMT, and p16 genes was determined using specific primers for methylated (M) and unmethylated (UM) DNA. Negative control specimens (without DNA) were included in each PCR set. PCR products were analysed on 4% ethidium bromidestained agarose gel and visualized under UV \[[@b17-cmh-2019-0051]-[@b19-cmh-2019-0051]\].

Statistical analysis
--------------------

Statistical analysis was done using IBM SPSS Statistics 21.0 (International Business Machines Corporation Company, New York, NY, USA). For categorical variables, percentages were calculated, and differences were analysed with chi square tests and Fisher's exact test when appropriate. Continuous variables were analysed as mean±standard deviation or median and range as appropriate. Differences among continuous variables with normal distribution were analysed by Student's *t*-test; comparison between three groups was done using Kruskel-Wallis test (non-parametric analogue for analysis of variance). *P*-value which is less than (0.05) was considered statistically significant.

RESULTS
=======

Clinico-pathological features of the patients
---------------------------------------------

The demographic, laboratory, and histopathological data of the 159 patients (81 responders and 78 non-responders) are illustrated in [Table 1](#t1-cmh-2019-0051){ref-type="table"}. No significant difference was observed between the two groups (responders and non-responders) regarding age, sex, haematological parameters, liver profile, HCV viral load. However, a significant difference was found in other variables such as BMI, Fibrosis, necroinflammatory activity, and steatosis ([Table 1](#t1-cmh-2019-0051){ref-type="table"}).

HCV RNA results
---------------

For HCV RNA levels by RT-PCR technique, there was no significant difference (*P*=0.789) between responders (193.000±108) and non-responders (338.000±237) for the 159 CHC patients before treatment ([Table 1](#t1-cmh-2019-0051){ref-type="table"}). HCV RNA results at different treatment end points and follow up of our patients were done to detect treatment response as shown in [Table 3](#t3-cmh-2019-0051){ref-type="table"}.

Methylation frequency of the studied genes in plasma samples
------------------------------------------------------------

The methylation frequency of SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, 6MGMT, and p16 genes for chronic HCV-4 Egyptian patients and healthy control group is shown in [Table 4](#t4-cmh-2019-0051){ref-type="table"}, [Figure 1](#f1-cmh-2019-0051){ref-type="fig"}, [2](#f2-cmh-2019-0051){ref-type="fig"}. Regarding the patients' response to antiviral therapy, the percentage of non-responders for APC, O6MGMT, RASSF1A, SFRP1, and p16 methylated genes were significantly (*P*\<0.05) higher versus responders ([Table 4](#t4-cmh-2019-0051){ref-type="table"}, [Fig. 2](#f2-cmh-2019-0051){ref-type="fig"}), where it was 75.6%, 75.8%, 69.4%, 63.7%, and 65% versus 24.4%, 24.2%, 30.6%, 36.3%, and 35% for APC, O6MGMT, RASSF1A, SFRP1, and p16 methylated genes respectively.

Of the 159 included patients, the most frequent methylated genes were SFRP1 (102/159), followed by p16 (100/159), RASSF1A (98/159), then LINE1 (81/159), P73 (81/159), APC (78/159), DAPK (66/159), O6MGMT (66/159), and p14 (54/159) ([Fig. 1](#f1-cmh-2019-0051){ref-type="fig"}).

Promotor methylation index
--------------------------

It defined as the ratio between the number of methylated genes and the total number of the studied genes for each sample was calculated for all patients \[[@b19-cmh-2019-0051]\]. For methylation index, no significant difference was found between responders and non‐responders (2.65±1.31 and 2.71±1.23; *P*=0.67) respectively. Also, there is no significant difference between mild fibrosis (F1 and F2) and marked fibrosis (F3 and F4) except for RASSF1A (*P*=0.024) and p16 (*P*=0.03) methylated genes ([Table 5](#t5-cmh-2019-0051){ref-type="table"}).

DISCUSSION
==========

The foremost predictors of response to interferon-based HCV therapy included both patient and viral factors. Patient factors that were associated with worse response to interferon-based therapy included male gender, older age, high BMI, advanced liver fibrosis, history of failed treatment, black race, non-CC IL28B genotype, and the presence of certain comorbid conditions, such as HIV coinfection, insulin resistance, or diabetes. Viral factors that were associated with worse response included non-genotype-2 infection, high viral load, and unfavourable viral kinetics during treatment \[[@b4-cmh-2019-0051],[@b20-cmh-2019-0051]\].

Some authors have revealed that hepatitis viruses infection might play a role in fast-tracking the methylation process which is involved in HCC development, and affect its response to treatment \[[@b6-cmh-2019-0051],[@b19-cmh-2019-0051],[@b21-cmh-2019-0051],[@b22-cmh-2019-0051]\]. Progression from chronic hepatic inflammation to the fibrotic/cirrhotic stage is supported by numerous core pathways, observed in other fibrotic diseases, as well as tissue- or injuryspecific pathways that are only activated in particular conditions \[[@b12-cmh-2019-0051],[@b13-cmh-2019-0051]\].

In an early work done by our group \[[@b16-cmh-2019-0051]\], detection of APC, FHIT, p15, p16 and E-cadherin-PM (range, 67.9--89.2%) had been done in the plasma and tissues of 28 chronic HCV and/or HBV-associated HCC patients, with a high concordance for all studied genes. However, no significant association was found, in this study, between the methylation status of any gene and the presence of hepatitis virus infection. This was partially attributed to the small sample size in this study. Then, we assessed the contribution of methylation status to the development and progression of HCVassociated HCC and CH in Egyptian patients using a specific panel of genes (APC, FHIT, p15, p73, p14, p16, DAPK1, CDH1, RARb, RASSF1A, O6MGMT) \[[@b19-cmh-2019-0051]\]. We found that HCV infection may contribute to hepatocarcinogenesis through enhancing PM of certain genes. A panel of 4 genes (APC, p73, p14, O6MGMT) out of 11 tested genes successfully classified cases into HCC or CH with high accuracy (89.9%), sensitivity (83.9%) and specificity (94.7%). A more extended confirmatory study, including 516 Egyptian patients with HCV-related liver disease (208 HCC, 108 liver cirrhosis, 100 CHC, and 100 controls), was then performed to detect PM of P14, P15, P73 and Mismatch repair gene (O6MGMT) in patient's plasma by using EpiTect Methyl qPCR Array technology \[[@b23-cmh-2019-0051]\]. The candidate genes selection (SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, O6MGMT, and p16) of the present work was analyzed by the Gene Expression Profiling Interactive Analysis database.

In the current study, significant efforts had been done to elucidate the role of PM to the response to antiviral therapy and its contribution to the development of fibrosis using some hepatocarcinogenesis-related genes. Percentage of non-responders for APC, O6MGMT, RASSF1A, SFRP1, and p16 methylated genes were significantly (*P*\<0.05) higher than those in responders. The most frequent methylated genes in the 159 CHC patients was SFRP1 (102/159), followed by p16 (100/159), RASSF1A (98/159), then LINE1 (81/159), P73 (81/159), APC (78/159), DAPK (66/159), O6MGMT (66/159), and p14 (54/159). In a previous study done by Iyer et al. \[[@b16-cmh-2019-0051]\], they detected a high frequency of 5 methylated genes (APC, FHIT, p15, p16 and E-cadherin) which ranged from 67.9% to 89.2% in the plasma and tissues of 28 chronic HCV and/or HBV-associated HCC patients. Although, no significant association was found in his study between the methylation status of any gene and the presence of hepatitis virus infection which could be attributed to the small sample size. Also, in a previous study done by our group \[[@b7-cmh-2019-0051]\], we assessed the contribution of methylation status to the development and progression of HCV-associated HCC and CH in Egyptian patients using a specific panel of genes (APC, FHIT, p15, p73, p14, p16, DAPK1, CDH1, RARb, RASSF1A, O6MGMT). We found that HCV infection may contribute to hepatocarcinogenesis through enhancing the promotor methylation of certain genes. On the other hand, Huang et al. \[[@b14-cmh-2019-0051]\], determined whether methylation status in plasma could be employed for monitoring the multistep carcinogenesis, multiplex MSP was applied to assay the methylation status for p16, SFRP1, and LINE1 in plasma specimens of 119 HCC patients, 105 LC patients, 52 patients with benign lesions and 50 healthy people. Therefore, Huang et al. \[[@b14-cmh-2019-0051]\] found that the modification in the expression of p16, SFRP1, and LINE1 genes might be involved in the process of hepatocarcinogenesis.

The present work has shown that the most frequent methylated genes in the 159 CHC patients were SFRP1, p16, RASSF1A, APC, and O6MGMT, where they were 102 (64.2%), 100 (62.9%), 98 (61.6%), 78 (49.1%), and 66 (41.5%), respectively. This finding does not go well with the previous study done by Zekri et al. \[[@b7-cmh-2019-0051]\] where they found that 06MGMT had the highest methylation frequency among HCV infected patients (64.2%) followed by p73 (50.9%), APC (49.1%), RASSF1A/DAP-kinase (41.5%), and p14 (34%). This discrepancies in results might be attributed to a small sample size of his study, where it was done on 53 CHC cases comparing to 159 chronic HCV patients and 100 healthy controls of the current work.

For the PM of the studied genes and degree of fibrosis, 67/98 (68.4%) cases of RASSF1A methylated gene (*P*=0.0.024) and 62/100 (62%) cases of p16 methylated gene (*P*=0.03) were associated with mild fibrosis. This finding was close to the results that found by Zekri et al. \[[@b7-cmh-2019-0051]\] where they stated that only PM of the RASSF1A gene was significantly associated with mild fibrosis in the studied patients (*P*=0.0.019). However, his study was done on six genes (p14, p73, APC, DAPK, RASSF1A, and O6MGMT) of 53 chronic HCV patients while our study was applied on nine genes (SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, O6MGMT, and p16) of 159 CHC patients. This finding might be explained by the fact that DNA methylation modification is played by the HCV core protein which inhibit the expression of the CDKN2A gene, that encodes for p16INK (inhibitor of cell proliferation) by up-regulating the methyltransferases DNMT1 and DNMT3b \[[@b24-cmh-2019-0051],[@b25-cmh-2019-0051]\]. Moreover, HCV core protein also increases the methylation of RASSF1A promoter, a negative regulator of the Ras pathway, by inducing the histone methyltransferase SMYD3 \[[@b25-cmh-2019-0051],[@b26-cmh-2019-0051]\]. Therefore, our results provide an evidence for the role of RASSF1A, and p16 genes in the induction of fibrogenesis in chronic HCV patients.

In conclusion, the PM of SFRP1, APC, RASSF1A, O6MGMT, and p16 genes increases in CHC patients. These methylated genes can significantly affect patients' response to antiviral treatment, whereas RASSF1A and p16 genes are involved in the process of fibrogenesis and possibly will have a role in the distinction between mild and marked fibrosis in those patients.
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###### 

Clinico-pathological features of 159 Egyptian patients with chronic genotype 4 hepatitis C

  Variable                           Responders (n=81)   Non-responders (n=78)   Total             *P*-value
  ---------------------------------- ------------------- ----------------------- ----------------- ----------------------------------------------------------------------------
  Age (years)                        37.8±6.8            40.8±9.0                38.1±8.9          0.462
  Sex, M/F                           75/12               60/12                   135/24            0.805
  BMI (kg/m^2^)                      26.51±3.86          70.06 ±11.79            49.7 ± 8.9        0.03^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^
  WBC (2.5--30.0×10^3^/mm^3^)        6.5±2.4             6.3±1.7                 6.4 ± 2.1         0.149
  Hemoglobin (9--17 gm/dL)           14.2±1.5            14.2±1.7                14.2±1.6          0.641
  Platelets (100--600×10^3^/mm^3^)   188.1±63.6          209.3±65.7              197.7± 64.8       0.683
  Albumin (3.5--5.5 gm/dL)           4.2 ± 0.4           4.1 ± 0.3               4.2 ± 0.5         0.207
  Total bilirubin (0.1--1.2 mg/dL)   0.78±0.21           0.80±0.33               0.79±0.27         0.116
  ALT (0--42 IU/L)                   101.11±181.11       121.35±401.73           118.11±231.11     0.617
  AST (0--42 IU/L)                   52.30±30.23         62.35±32.73             57.23±31.59       0.155
  ALP (0--290 IU/L)                  124.81±72.43        107.81±64.30            116.47±68.45      0.406
  AFP (0--10 ng/mL)                  5.3 ± 7.3           7.2 ± 10.4              10.1±1.5          0.346
  HCV viral load (IU/mL)             193.000±108.000     338.000±237.000         244.231±101.000   0.789
  Fibrosis                                                                                         
   Mild to moderate (F1 & F2)        63 (77.7)           57 (73.1)               120 (75.5)        0.03^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^ (F1 & F2 vs. F3 & F4)
   Marked (F3 & F4)                  18 (22.3)           21 (26.9)               39 (24.5)         
  Necroinflammatory activity                                                                       0.01^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^ (A1 & A2 vs. A3 & A4)
   A1 & A2                           69 (85.1)           72 (92.3)               141 (88.6)        
   A3 & A4                           12 (14.9)           6 (7.7)                 18 (11.4)         
  Steatosis                                                                                        0.459
   None                              18 (66.7)           9 (33.3)                27 (17)           
   Minimal                           9 (42.9)            12 (57.1)               21 (13.2)         
   Mild                              47 (54)             39 (44.8)               87 (54.7)         
   Moderate                          12 (50)             12 (50)                 24 (15.1)         

Values are presented as mean±standard deviation or number (%).

M, male; F, female; BMI, body mass index; WBC, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; AFP, α-fetoprotein; HCV, hepatitis C virus.

###### 

Primers sequences and conditions of the methylation specific PCR

  Gene                                                  Primer sequence                      AT (°C)   MgCl~2~ (mM)   No. of cycles
  ----------------------------------------------------- ------------------------------------ --------- -------------- ---------------
  SFRP1 \[[@b17-cmh-2019-0051]\]                                                                                      
   MF                                                   TTT AGT AAA TCG AAT TCG TTC GC       60        4.5            40
   MR                                                   TAA AAT ACG CGA AAC TCC TAC G                                 
   UF                                                   TTT TAG TAA ATT GAA TTT GTT TGT GA   60        4.5            40
   UR                                                   TAA AAT ACA CAA AAC TCC TAC AAC                               
  p14 \[[@b18-cmh-2019-0051]\]                                                                                        
   MF                                                   GTGTTAAAGGGCGGCGTAGC                 54        4.5            35
   MR                                                   AAAACCCTCACTCGCGACGA                                          
   UF                                                   TTTTTGGTGTTAAAGGGTGGTGTAGT           56        4.5            35
   UR                                                   CACAAAAACCCTCACTCACAACAA                                      
  p73 \[[@b18-cmh-2019-0051]\]                                                                                        
   MF                                                   GGACGTAGCGAAATCGGGGTTC               62        4.5            35
   MR                                                   ACCCCGAACATCGACGTCCG                                          
   UF                                                   AGGGGATGTAGTGAAATTGGGGTTT            62        4.5            35
   UR                                                   ATCACAACCCCAAACATCAACATCCA                                    
  APC \[[@b19-cmh-2019-0051]\]                                                                                        
   MF                                                   TATTGCGGAGTGCGGGTC                   62        4.5            35
   MR                                                   TCAACGAACTCCCGACGA                                            
   UF                                                   GTGTTTTATTGTGGAGTGTGGGTT             59.2      4.5            35
   UR                                                   CCAATCAACAAACTCCCAACAA                                        
  DAPK \[[@b18-cmh-2019-0051]\]                                                                                       
   MF                                                   GGATAGTCGGATCGAGTTAACGTC             59        4.5            35
   MR                                                   CCCTCCCAAACGCCGA                                              
   UF                                                   GGAGGATAGTTGGATTGAGTTAATGTT          59        4.5            35
   UR                                                   CAAATCCCTCCCAAACACCAA                                         
  RASSF1A \[[@b19-cmh-2019-0051]\]                                                                                    
   MF                                                   TTCGTCGTTTAGTTTGGATTTTG              54.4      4.5            35
   MR                                                   CCGATTAAACCCGTACTTCG                                          
   UF                                                   TGTTGTTTAGTTTGGATTTTGG               52        4.5            35
   UR                                                   TACAACCCTTCCCAACACAC                                          
  LINE1 \[[@b27-cmh-2019-0051],[@b28-cmh-2019-0051]\]                                                                 
   MF                                                   GCGCGAGTCGAAGTAGGGC                  60        4.5            40
   MR                                                   CTCCGACCAAATATAAAATATAATCTCG                                  
   UF                                                   ATTTTAGTATTTTGGGAGGTCGAGGC           60        4.5            40
   UR                                                   GCAATCTCGACTCACTACAAA CTCCG                                   
  O6MGMT \[[@b18-cmh-2019-0051]\]                                                                                     
   MF                                                   TTTCGACGTTCGTAGGTTTTCGC              56        3.5            35
   MR                                                   GCACTCTTCCGAAAACGAAACG                                        
   UF                                                   TTTGTGTTTTGATGTTTGTAGGTTTTTGT        56        4.5            35
   UR                                                   AACTCCACACTCTTCCAAAAACAAAACA                                  
  p16 \[[@b18-cmh-2019-0051]\]                                                                                        
   MF                                                   TTATTAGAGGGTGGGGCGGATCGC             68        1.5            33
   MR                                                   GACCCCGAACCGCGACCGTAA                                         
   UF                                                   TTATTAGAGGGTGGGGTGGATTGT             58        4.5            33
   UR                                                   CAACCCCAAACCACAACCATAA                                        

PCR, polymerase chain reaction; AT, annealing temperature; MF, methylated forward; MR, methylated reverse; UF, unmethylated forward; UR, unmethylated reverse.

###### 

HCV RNA of the 159 CHC patients at different treatment end points

  HCV RNA (+/-) by RT-PCR after weeks   Non-responder (n=78)   Responder (n=81)   Total         *P*-value
  ------------------------------------- ---------------------- ------------------ ------------- ---------------------------------------------------------
  PCR-W12                                                                                       
   Negative                             69 (46.0)              81 (54.1)          150 (100.0)   
   Positive                             9 (100.0)              0 (0.0)            9 (100.0)     0.032^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^
   Total                                78 (49.1)              81 (50.9)          159 (100.0)   
  PCR-W24                                                                                       
   Negative                             66 (44.9)              81 (55.1)          147 (100.0)   
   Positive                             12 (100.0)             0 (0.0)            12 (100.0)    0.022^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^
   Total                                78 (49.1)              81 (50.9)          159 (100.0)   
  PCR-W48                                                                                       
   Negative                             27 (25.0)              81 (75)            108 (100.0)   
   Positive                             51 (100.0)             0 (0.0)            51 (100.0)    \<0.001^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^
   Total                                78 (49.1)              81 (50.9)          159 (100.0)   
  PCR-W72                                                                                       
   Negative                             6 (6.9)                81 (93.1)          87 (100.0)    
   Positive                             72 (100.0)             0 (0.0)            72 (100.0)    \<0.001^[\*](#tfn1-cmh-2019-0051){ref-type="table-fn"}^
   Total                                78 (49.1)              81 (50.9)          159 (100.0)   

Values are presented as number (%).

HCV, hepatitis C virus; CHC, chronic hepatitis C; RT-PCR, reverse transcription-polymerase chain reaction; W, weeks.

*P*-value \<0.05 is considered significant.

###### 

Methylation frequency of the studied genes for 159 Egyptian patients with chronic genotype 4 hepatitis C in relation to treatment response

  Methylation status   Response to treatment   Total (n=159)   Control (n=100)   *P*-value   
  -------------------- ----------------------- --------------- ----------------- ----------- -------------------------------------------------------
  SFRP1                                                                                      
   M                   65 (63.7)               37 (36.3)       102 (64.2)        5 (5.0)     0.043^[\*](#tfn2-cmh-2019-0051){ref-type="table-fn"}^
   U                   13 (22.8)               44 (77.2)       57 (35.8)         95 (95.0)   
  p14                                                                                        
   M                   27 (50.0)               27 (50.0)       54 (34.0)         6 (6.0)     0.930
   U                   51 (48.6)               54 (51.4)       105 (66.0)        94 (94.0)   
  p73                                                                                        
   M                   45 (55.6)               36 (44.4)       81 (50.9)         4 (4.0)     0.328
   U                   33 (42.3)               45 (57.7)       78 (49.1)         96 (96.0)   
  APC                                                                                        
   M                   59 (75.6)               19 (24.4)       78 (49.1)         5 (5.0)     0.02^[\*](#tfn2-cmh-2019-0051){ref-type="table-fn"}^
   U                   19 (23.5)               62 (76.5)       81 (50.9)         95 (95.0)   
  DAPK                                                                                       
   M                   24 (36.4)               42 (63.6)       66 (41.5)         7 (7.0)     0.097
   U                   54 (58.1)               39 (41.9)       93 (58.5)         93 (93.0)   
  RASSF1A                                                                                    
   M                   68 (69.4)               30 (30.6)       98 (61.6)         5 (5.0)     0.031^[\*](#tfn2-cmh-2019-0051){ref-type="table-fn"}^
   U                   10 (22.0)               51 (78.0)       61 (38.4)         94 (94.0)   
  LINE1                                                                                      
   M                   46 (56.8)               35 (43.2)       81 (50.9)         4 (4.0)     0.37
   U                   32 (41.0)               46 (59.0)       78 (49.1)         96 (96.0)   
  O6MGMT                                                                                     
   M                   50 (75.8)               16 (24.2)       66 (41.5)         7 (7.0)     0.021^[\*](#tfn2-cmh-2019-0051){ref-type="table-fn"}^
   U                   28 (23.7)               65 (76.3)       93 (58.5)         93 (93.0)   
  p16                                                                                        
   M                   65 (65.0)               35 (35.0)       100 (62.9)        6 (6.0)     0.04^[\*](#tfn2-cmh-2019-0051){ref-type="table-fn"}^
   U                   13 (22.0)               46 (78.0)       59 (37.1)         94 (94.0)   

Values are presented as number (%).

M, methylated; UM, unmethylated.

*P*-value \<0.05 is considered significant.

###### 

Correlation between methylation of the studied genes and degree of fibrosis

  Methylated gene   Mild fibrosis (F1 & F2) (n=120; 75.5%)   Marked fibrosis (F3 & F4) (n=39; 24.5%)   *P*-value
  ----------------- ---------------------------------------- ----------------------------------------- -------------------------------------------------------
  SFRP1             47/102 (46.0%)                           55/102 (54.0%)                            0.68
  p14               26/54 (48.2%)                            28/54 (51.8%)                             0.73
  p73               36/81 (44.5%)                            45/81 (55.5%)                             0.69
  APC               36/78 (46.2%)                            42/78 (53.8%)                             0.45
  DAPK              29/66 (43.9%)                            37/66 (56.1%)                             0.36
  RASSF1A           67/98 (68.4%)                            31/98 (31.6%)                             0.024^[\*](#tfn3-cmh-2019-0051){ref-type="table-fn"}^
  LINE1             35/81 (43.2%)                            46/81 (56.8%)                             0.35
  O6MGMT            36/66 (54.4%)                            30/66 (45.6%)                             0.68
  p16               62/100 (62.0%)                           38/100 (38.0%)                            0.03^[\*](#tfn3-cmh-2019-0051){ref-type="table-fn"}^

*P*-value \<0.05 is considered significant.
